As was suggested previously, KCa3.1 and KCa2.3 channel may represent novel and effective therapeutic targets for the treatment of cardiovascular diseases associated with endothelial dysfunction [12,52]. This evidence concerns the gene KCNN3 and cardiovascular disorder.